Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
148 participants
INTERVENTIONAL
2022-02-03
2023-05-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Sleep Deprivation on Antidepressant Response
NCT00178074
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
NCT03537794
Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients
NCT06101914
Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module.
NCT04518592
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
NCT01874951
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ALTO-300
ALTO-300 tablet PO; daily dosing 8 weeks
ALTO-300 PO Tablet
One tablet daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ALTO-300 PO Tablet
One tablet daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Currently taking a SSRI, SNRI, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks
* Must have failed to adequately respond to the current antidepressant medication
* Willing to comply with all study assessments and procedures
* Must not be pregnant or breastfeeding at time of enrollment or throughout study
Exclusion Criteria
* Active suicidal ideation
* Moderate to severe Alcohol Use Disorder
* Diagnosed bipolar disorder or psychotic disorder
* Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients
* Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alto Neuroscience
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cerebral - Atlanta
Atlanta, Georgia, United States
Site 171
Jackson, Mississippi, United States
Cerebral - New York City
New York, New York, United States
Cerebral - Dallas
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALTO-300-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.